FDA moves to yank liquid statin FloLipid off US shelves
The FDA wants to pull its approval of FloLipid, a liquid simvastatin sold by Oklahoma-based Salerno Pharmaceuticals, after the company repeatedly skipped required annual reports and ignored the agency's requests. Without approval, the 20-mg and 40-mg doses could no longer be legally sold across the US.
- Original source: cardiovascularbusiness.com.
- The source published it on Nov 18, 2026 at 12:56 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA has proposed withdrawing its approval of FloLipid, the liquid simvastatin made by Oklahoma-based Salerno Pharmaceuticals, after the manufacturer failed on multiple occasions to file required reports — and failed to answer the agency's requests for them. The move, signed by Michael Davis, MD, PhD, director of the FDA's Center for Drug Evaluation and Research, would effectively take the drug off shelves nationwide.
The proposal covers the 20-mg and 40-mg doses of the liquid statin, which Salerno markets as the first cholesterol medication in liquid form for U.S. patients. It was designed for people who struggle to swallow pills and does not need refrigeration. The FDA first approved the company's simvastatin formulation in 2016.
Companies that win approval of a new drug application must file annual reports to keep it. According to the Federal Registrar, Salerno has until Dec. 18 to request a hearing, then until Jan. 19, 2027, to hand over all relevant data and written comments.
If the company misses the hearing deadline, the FDA says that counts as a waiver of any arguments about the drug's legal status. The proposal states the agency would then withdraw approval, and the products could no longer be lawfully introduced or delivered into interstate commerce. Any new drug product shipped without an approved NDA, the FDA adds, is subject to regulatory action at any time.
TopicsFDA · Salerno Pharmaceuticals · FloLipid · simvastatin · Michael Davis · Center for Drug Evaluation and Research
Source: cardiovascularbusiness.com
Written by AI from verified reporting.
More stories
- Health & science cnbc.com Caught by @bayu.lestari45 0 viewsFDA's Case Against Cheap-Drug Sellers Rests on a Rival CEO Turned Informant
- Health & science x.com 0 viewsAdults Ask About Another Measles Shot as US, Mexico and Bolivia Lose Elimination Status
- Health & science finance.yahoo.com 1 viewIonis' Tryngolza becomes EU's first RNA therapy for severe high triglycerides
- Health & science theguardian.com 0 viewsE coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise

